Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for ...

Barclays 28th Annual Global Healthcare Conference March 12, 2026 8:30 AM EDTCompany ParticipantsAmy Parison - Senior VP ...

ProQR’s collaboration with Eli Lilly and Company (Lilly) continued to progress in 2025, resulting in $4.5 million in ...

Cancer is caused by faulty genes, but what also shapes a cancer cell's behavior is how a gene's instructions are trimmed and ...

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.

The new financing was led by Venrock Healthcare Capital Partners with participation from other new and existing investors.

The molecular pathways involved in antiviral defenses and counter-defenses in host-pathogen systems remain unclear. Researchers have used Neurospora crassa as a model organism to explore how RNA ...

Rice University researchers have developed a CRISPR-based gene activation strategy that boosts mitochondrial production in damaged heart cells, improving cardiac function after heart attacks in both ...

On March 9, Korro disclosed it had entered a subscription agreement to sell 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for another 3,148,836 shares, a transaction ...

As climate pressure mounts, new platforms tackle delivery, regulation, trait stacking, and data bottlenecks limiting agricultural genome editing.

Better mRNA release inside cells boosts vaccine and gene editing performance, enabled by redesigned lipid molecules that grip ...

Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investorsProceeds support the ...